Etanercept: An overview

  • J Am Acad Dermatol. 2003 Aug;49(2 Suppl):S105-11. doi: 10.1016/mjd.2003.554.
Ben Goffe  1 ,  Jennifer Clay Cather
Affiliations
  • 1. Department of Dermatology, University of Washington, 515 Minor Avenue, Suite 200, Seattle, WA 98104, USA. [email protected]
PMID: 12894133 DOI: 10.1016/mjd.2003.554
Abstract

Etanercept, a competitive inhibitor of TNF-alpha, is currently FDA approved for psoriatic Arthritis and Rheumatoid Arthritis. The molecular structure of etanercept, its mechanism of action, and results of clinical trials involving patients with Psoriasis will be reviewed.

Products